福泰制药
VRTX
查看详细走势图
455.243USD
+4.008+0.89%
交易中 （美东）报价延迟15分钟
95.99B总市值
29.45市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+0.89%
5天
-1.57%
1月
-6.60%
6月
+20.88%
今年开始到现在
+0.42%
1年
-11.04%
查看详细走势图
TradingKey 福泰制药股票评分
单位: USD 更新时间: 2026-03-24操作建议
福泰制药当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在药品行业排名12/157位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价547.01。中期看，股价处于平稳状态。近一个月，市场表现较差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
福泰制药评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看好
福泰制药亮点
亮点风险
Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
业绩高增长
公司营业收入稳步增长，连续3年增长21.60%
业绩转盈
公司业绩转盈，最新年度盈利美元
估值合理
公司最新PE估值29.02，处于3年历史合理位
机构减仓
最新机构持股248.62M股，环比减少1.80%
特威迪·布朗持仓
明星投资者特威迪·布朗持仓，最新持仓市值39.15K
活跃度增加
近期活跃度增加，过去20天平均换手率0.81
分析师目标
根据
34
位分析师
买入
评级
547.012
目标均价
+20.49%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
福泰制药新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
福泰制药简介
Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
公司代码VRTX
公司福泰制药
CEOKewalramani (Reshma)
网址https://www.vrtx.com/
相关品种
